The protein kinase C (PKC) family of serine/threonine-specific protein kinases is involved in many cellular processes, and the-unregulated activation of PKC has been implicated in carcinogenesis. PKC inhibitors thus have significant potential as chemotherapeutic agents. Recently, the fungal metabolite balanol was shown to be an exceptionally potent inhibitor of PKC. We previously developed a practical and efficient total synthesis of balanol. We set out to use this synthetic molecule, and several synthetic analogs, to probe the mechanism of PKC inhibition and to determine the effect of balanol on the activity of other protein kinases. Results 
:
As well as inhibiting PKC, balanol is a potent inhibitor of cyclic AMP-dependent protein kinase (P&4), another protein serine/threonine kinase. Balanol does not, however, inhibit the Src or epidermal growth factor receptor protein tyrosine kinases. The inhibition of both PKC and PKA by balanol can be overcome by high concentrations of ATP, and molecular modeling studies suggest that balanol may function as an ATP structural analog. Although balanol discriminates rather poorly between PKC and PKA, only minor modifications to its molecular structure are required to furnish compounds that are highly specific inhibitors of PKA.
Conclusions:
A number of balanol analogs have been designed and synthesized that, unlike balanol itself, exhibit dramatic selectivity between PKA and PKC. Thus, despite the substantial homology between the catalytic domains of PKA and PKC, there is enough difference to allow for the development of potent and selective inhibitors acting in this region. These inhibitors should be useful tools for analyzing signal transduction pathways and may also aid in the development of drugs with significant therapeutic potential.
Introduction
The protein kinase C (PKC) family of enzymes [l-7] Balanol also inhibited the activity of the catalytic (C) subunit of the cyclic AMP-dependent protein kinase (PKA) ]14-211, with an IC,, of 4 nM (Fig. 3a) , identical to that for inhibition of PKC. The competition profiles were similar to those for PKC. Increasing concentrations of phosphate acceptor did not overcome the effect of balanol (Fig. 3b) , h w ereas ATP at sufficiently high concentrations did (Fig. 3c ), implying that balanol was acting competitively with ATP Results obtained with the purified recombinant C subunit of PKA (cPKA) and with the holoenzyme (purified from rabbit muscle) assayed in the presence of CAMP were similar.
The effectiveness of balanol as an inhibitor of PKA and PKC, both protein serine/threonine kinases, raised the question of specificity of balanol toward protein kinases in general. We tested balanol against two protein tyrosine kinases, the epidermal growth factor receptor (EGFR) kinase and the Src kinase (pp60 Src). Balanol did not inhibit either of these protein kinase activities, whereas known inhibitors were effective (Fig. 4) . Tested against this small number of protein kinases, balanol seems effective against protein serine/threonine kinases and ineffective against protein tyrosine kinases. The effect of balanol on a broader range of protein kinases is currently under investigation.
Molecular modeling studies for balanol
To gain further insight into the action of balanol, and to aid our design of novel balanoids, we generated a structural model of the inhibitor through a combination of conformational analysis (using Monte Carlo methods) and ab initio calculations. An initial conformation for balanol (neutral non-zwitterionic form) was constructed using the program MacromodelV3.5X
and energy minimized in the MM2 force field (500 steps of energy minimization using a conjugate gradient algorithm). A Monte Carlo conformational search was then performed using a water solvation model [22] , allowing complete freedom of movement for all the rotatable bonds to search for the global minimum energy conformation. This conformation was then optimized using the PM3 program contained in the MOPAC software package (128 steps of against PKA (Fig. 7a) suggested that the complete balanol backbone should be retained for inhibitory activity. The molecular modeling analysis described above demonstrated that the oxygen-rich benzophenone fragment of balanol could correspond to the triphosphate region of ATP To examine the importance of this region, the analogs lo"-deoxybalanol (4), 14"-decarboxybalanol (5), and 4",6"-dideoxybalanol (6) were prepared [13] . 
Biological evaluation of balanol analogs (4-7)
The inhibitory activities of balanol and its analogs 4-7 against PKC and cPKA are shown in Figure 7 and compared in Table 1 = 18 nM). Analogs 6 and 7 both inhibited cPKA with IC,, values similar to that of balanol (5.5 nM and 5.7 nM, respectively) but were significantly less active as PKC inhibitors (IC,, = 111 nM and 95 nM, respectively). The high potency of the decarboxylated analog (7) for inhibition of cPKA suggests that a hydrogenbonding interaction with the hydrophobic portion of balanol is not essential for binding.
The lo"-deoxybalanol analog (4) and the 14"-decarboxybalanol analog (5) exhibited the most dramatic selectivity for cPKA. These analogs were found to be approximately as potent as balanol for the inhibition of cPKA (IC,, = 6.3 nM and 18 nM, respectively) but were 125-fold to lOOO-fold less effective than balanol against PKC (IC,, = 834 nM and 6.9 PM, respectively).
It is important to note that the inhibition of cPKA by lo"-deoxybalanol (4) also could be overcome by high concentrations of ATP (data not shown), thus confirming that these new balanoids were also acting at the ATP-binding site.
The observation that such minor structural alterations can lead to a marked differentiation in protein kinase selectivity suggests that the binding of balanol at the catalytic Figure 6 for the names and structures of compounds 2-7. 
Significance
The modulation of protein activity through phosphorylation by protein kinases is fundamental to the control of many different cellular events. In particular, the signal transduction pathways that are regulated by PKC and PKA are now highly delineated and it is clear that selective inhibitors of these enzymes could prove therapeutically useful. PKC and PKA are both serine/threonine-specific protein kinases and have a high degree of homology in their catalytic domains. This homology is presumably reflected in the observation that inhibitors acting at the catalytic domains of these enzymes are generally non-selective (e.g. staurosporine).
High enzyme selectivity is, however, essential for any inhibitor to be of value either as a tool for signal transduction research or as a potential drug candidate.
We have shown that the fungal metabolite balanol, originally reported as a PKC inhibitor, also inhibits PKA. Nevertheless, based on molecular modeling studies, a number of new analogs of balanol have been designed and synthesized that show significant selectivity for the inhibition of PKA over PKC. In particular, lo"-deoxybalanol (compound 4) and 14"-decarboxybalanol (compound 5) are remarkably potent and selective inhibitors of PKA. Thus, although the catalytic domains of PKA and PKC show a high degree of homology and probably share a common mechanism for phosphoryl transfer, they are sufficiently different to allow the development of potent and selective inhibitors that act at the ATP-binding region.
Materials and methods

Materials
All of the analogs described here were prepared by chemical synthesis, as described elsewhere [13] .
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